 |
|
Advanced Melanoma of the ExtremitiesTreatment by Isolation-Perfusion With a Triple Drug Combination
Charles M. McBride, MD
AMA Arch Surg. 1970;101(2):122-126.
Abstract
Fifty patients with advanced melanoma were perfused, using melphalan, dactinomycin, and mechlorethamine hydrochloride. At two years, one half of the patients are free from disease, and only one quarter have recurrence in the treated extremity. The first two years are critical for recurrences and metastasis, and the previous 21% five-year survival rate may be exceeded. Complications occurred in one third of the patients, but there were no deaths and no loss of limbs. Morbidity from complications did not persist more than six months. Previously, little improvement has occurred in the treatment of patients suffering from advanced melanoma, and revision of anticancer techniques and agents is necessary to insure the best patient treatment. This drug combination may have increased the effectiveness of regional chemotherapy such that some patients with advanced melanoma will obtain "clinical cures."
Author Affiliations
From the University of Texas M. D. Anderson Hospital and Tumor Institute, Houston.
Footnotes
Accepted for publication April 9, 1970.
Read before the 27th annual meeting of the Central Surgical Association, Detroit, Feb 26, 1970.
Reprint requests to M. D. Anderson Hospital and Tumor Institute, Houston 77025 (Dr. McBride).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Hemipelvectomy
Douglass et al.
Arch Surg 1975;110:82-85.
ABSTRACT
Sarcomas of the Limbs: Results of Adjuvant Chemotherapy Using Isolation Perfusion
McBride
Arch Surg 1974;109:304-308.
ABSTRACT
Recurrent Melanoma of an Extremity Treated by Major Amputation
Turnbull et al.
Arch Surg 1973;106:496-498.
ABSTRACT
|
